Head-to-head evidence
bimagrumab vs taldefgrobep alfa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Activin/myostatin type II receptor · full Obesity pipeline
bimagrumab
Developed by Eli Lilly under a licence from Novartis
NCT05616013 · Phase 2 · completed
This randomized, double-blind, placebo-controlled trial enrolled 507 adults and used a hard clinical primary endpoint, change in body weight at Week 48. The primary endpoint comparison showed a statistically significant advantage for most active treatment combinations over placebo, including the highest-dose combination (bimagrumab 30 mg/kg + semaglutide 2.4 mg), but the 10 mg/kg bimagrumab monotherapy arm missed significance, yielding a mixed primary endpoint result. Because the primary endpoint was not uniformly met across the multiple prespecified comparisons, the overall evidence is moderate despite the strong design.
Next expected readout: December 2028 · NCT05933499 (registry estimate)
taldefgrobep alfa
Developed by Biohaven
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bimagrumab's landscape · taldefgrobep alfa's landscape